Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients

被引:249
|
作者
Aberra, FN
Lewis, JD
Hass, D
Rombeau, JL
Osborne, B
Lichtenstein, GR
机构
[1] Univ Penn, Sch Med, Hosp Univ Penn, Dept Med,Div Gastroenterol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/S0016-5085(03)00883-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Many patients with inflammatory bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surgery. We investigated the postoperative infection risk for patients undergoing elective bowel surgery who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared with patients not receiving these medications. Methods: A retrospective cohort study was conducted on 159 patients with inflammatory bowel disease who underwent elective bowel surgery. There were 56 patients receiving corticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticosteroids, and 5:1 patients receiving neither corticosteroids nor 6-mercaptopurine/azathioprine. Postoperative infectious complications to time of discharge were categorized into major and minor complications. Results: Patients receiving corticosteroids had an adjusted odds ratio for any and major infectious complications of 3.69 (95% confidence interval [CI], 1.24-10.97) and 5.54 (95% CI, 1.12-27.26), respectively. The adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectious complications was 1.68 (95% CI, 0.65-4.27) and 1.20 (95% CI, 0.37-3.94), respectively. Conclusions: Preoperative use of corticosteroids in patients with inflammatory bowel disease who are undergoing elective bowel surgery is associated with an increased risk of postoperative infectious complications. 6-mercaptopurine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corticosteroids was not found to significantly increase the risk of postoperative infectious complications.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [31] Infectious Complications in IBD Patients on Immunomodulators, Corticosteroids, and Vedolizumab: Is Older Age a Predictor of Higher Complication Rates or Worsened Response?
    Grace, Rory
    Bownik, Hillary
    Scott, Frank
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S823 - S823
  • [32] Review article: practical management of inflammatory bowel disease patients taking immunomodulators
    Siegel, CA
    Sands, BE
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (01) : 1 - 16
  • [33] Recent Advances Using Immunomodulators for Inflammatory Bowel Disease
    Nielsen, Ole Haagen
    Bjerrum, Jacob Tveiten
    Herfarth, Hans
    Rogler, Gerhard
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (06): : 575 - 588
  • [34] Safe and Effective Use of Immunomodulators for Inflammatory Bowel Disease
    Siegel, Corey A.
    PRACTICAL GASTROENTEROLOGY, 2006, 30 (07) : 31 - 44
  • [35] Corticosteroids and immunosuppressors: risk 7 factors for inflammatory bowel disease surgery?
    Mortensen, NJ
    IBD AND SALICYLATES - 5, 2001, 24 (01): : 107 - 109
  • [36] Association of Thyroid Cancer with The Use of Biologics and Immunomodulators in Inflammatory Bowel Disease Patients
    Fialho, Andrea
    Fialho, Andre
    Kochhar, Gursimran
    Shen, Bo
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S33 - S34
  • [37] Review article: monitoring of immunomodulators in inflammatory bowel disease
    Aberra, FN
    Lichtenstein, GR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 307 - 319
  • [38] Predictors of postoperative morbidity in patients with inflammatory bowel disease
    Imperatore, N.
    Pellegrini, L.
    Bucci, L.
    Rispo, A.
    Guarino, A. D.
    Testa, A.
    Peltrini, R.
    Amendola, A.
    Patturelli, M.
    Castiglione, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S277 - S278
  • [39] Update: Meta-analysis of Overall Risk for Lymphoma with Immunomodulators for Inflammatory Bowel Disease
    Kotlyar, David
    Brensinger, Colleen
    Lewis, James
    Blonski, Wojciech
    Van Domselaar, Manuel
    Porter, David
    Sandilya, Sandeep
    Lichtenstein, Gary
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S423 - S424
  • [40] Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease
    Kreijne, J. E.
    Goetgebuer, R. L.
    Erler, N. S.
    De Boer, N. K.
    Siebers, A. G.
    Dijkstra, G.
    van Kemenade, F. A.
    Hoentjen, F.
    Oldenburg, B.
    van der Meulen, A. E.
    Ponsioen, C. I. J.
    Pierik, M. J.
    van der Woude, C. J.
    de Vries, A. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (02) : 207 - 217